Fibrobiologics Inc
Fibrobiologics Inc (ticker: FBLG) is a small‑cap biotechnology company focused on developing biologic therapies related to fibrotic conditions. With a market capitalisation of about $17.5 million, it is a relatively modest‑sized issuer, which typically means lower liquidity and greater share price volatility. Investors should expect long development timelines, potential funding needs, and regulatory hurdles common to early‑stage biotech firms. Key things to watch include clinical or preclinical programme updates, partnership or licensing deals, and quarterly financial filings that show cash runway. This summary is general, educational information only and not personalised advice. Biotech stocks can offer meaningful upside if programmes succeed, but they carry a high risk of failure and substantial share price moves. Suitability depends on an investor’s risk tolerance, timeframe and portfolio diversification; consider seeking regulated financial advice before investing.
Stock Performance Snapshot
Financial Health
Fibrobiologics shows a decent ability to generate cash, but its overall value per share is low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FBLG
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore Basket3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap volatility
Market moves can be sharp due to low liquidity and news sensitivity; potential gains exist but downside can be large, so size positions carefully.
Pipeline catalysts
Clinical readouts, regulatory steps or partnership deals can drive shares. These events are high‑impact and outcomes are uncertain.
Unmet medical need
Fibrotic diseases represent a meaningful market opportunity, but lengthy development and approval processes add risk for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
